TMO Thermo Fisher Scientific Inc.

$TMO might be one of the SLEEPIEST AI plays on Wall Street. Everyone is chasing the companies BUILDING AI data centers. But somebody has to monetize all that compute. Thermo Fisher is partnered with BOTH $NVDA and OpenAI to push AI into drug discovery, clinical trials, scientific instrumentation and fully automated laboratories. Think about the chain: AI DATA CENTERS → massive compute → AI drug discovery → automated labs → genomics/proteomics → TMO instruments, software, consumables and services. And this isn’t theoretical. 🔥 NVIDIA + Thermo Fisher strategic AI partnership 🔥 OpenAI + Thermo Fisher collaboration 🔥 AI-powered laboratory automation 🔥 AI-driven drug discovery 🔥 AI-enabled mass spectrometry & multiomics 🔥 $45B+ annual revenue powerhouse NVDA $AMD $VRT $DELL build the AI horsepower. TMO helps turn that horsepower into actual scientific breakthroughs and new drugs. The AI trade is expanding WAY beyond chips. Wall Street may eventually figure out that TMO is sitting right in the middle of the AI + healthcare + biotech convergence.

What's going on with $TMO? Pretty flat over the last five days Today saw some interesting options action A big Oct 16 $655 put sweep on the ask, about 1,025 contracts and $796k premium just popped up Looks like someone is hedging or betting on a drop If you’re long, keep those risk controls tight On the flip side, there were three separate sweeps in Oct 16 $750 calls Around 1,745 contracts in total That’s $205k in premium and 10% OTM Definitely some upside interest there, so it's not all bearish Overall, the setup is put-skewed but still two-sided No clear edge yet

$TMO is showing a major breakout on the monthly chart. 📈 After years of consolidation beneath long-term descending resistance, Thermo Fisher is finally pushing through the top of this large bullish pennant. The monthly candle is up roughly 10% and testing the prior highs around $680. ✅

$TMO Reports Wednesday before the open. Zacks consensus is 6.40 dollars of EPS, up 10.5% YoY, on 11.91 billion dollars of revenue, up 7.1%. The segment estimates are pretty uneven though. Life Sciences Solutions is expected up 10.1% and Laboratory Products up 9.8%, while Analytical Instruments is pegged at just plus 2.6% and Specialty Diagnostics is expected down 3%. TMO has beaten the Zacks consensus in each of the last four quarters, average surprise 4.42%.

$TMO cleared 694 on nearly 2x average volume and closed at a record 696.49. Holds above 694 and runs to 755. A close back under 673 and I'm wrong.

$TMO Our framework reflects a bullish read on Thermo Fisher Scientific, with 7 of 9 signal cells flashing positive at an average conviction score of 3.0 out of 5. As seen in the chart attached, this is our read as of 17 Sep 2026—it is a dated snapshot, not a live call. Fundamental tailwinds drive the core thesis: top-line expansion accelerated to 10.5% in the second quarter, while full-year 2026 revenue guidance was raised to $48.1 billion, underpinned by an unmatched life sciences moat. Technically, the equity maintains its broader upward trajectory by trading above both its 50-day and 200-day moving averages, even as short-term momentum shows neutral consolidation. We would turn bearish if revenue execution drops back below expectations or if price breaks below the 200-day moving average. (Disclosure: we're and this is our own research.)

$TMO huge multi month rally after performing poorly since Jan 2022 Co announced revenue growth above expectations